← Leaderboards
Alan Johnson
Hawaii Biotech, Inc.
$14,114,478
Attributed
$14,114,478
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $9M · FY2019–23$10M$7.5M$5M$2.5M$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$14,114,478 · 1
By mechanism
N01$14,114,478 · 1
Top collaborators
No co-investigators on record.
Most similar at Hawaii Biotech, Inc.
Same institution · by research overlap
- Alan Thomas Johnson$20,896,391
- Sean None O'Malley$1,926,175
- David E. Clements$13,267,458
Others in their field
Other Emerging Leaders on “Therapeutic Candidate”
- Urs Ochsner · Crestone, Inc.$40,390,611
- Ryan Cirz · Revagenix, Inc.$40,209,479
- Jeffrey Glenn · Stanford University$26,017,226
- Daniel Pevear · Venatorx Pharmaceuticals, Inc.$24,789,028
- Julie Ake · National Institute Of Allergy And Infectious Diseases$22,000,000
- Jinhong Chang · Baruch S. Blumberg Institute$16,016,617
Research focus
Therapeutic CandidateSafety AssessmentSmall MoleculeAdvanced DevelopmentAnthrax DiseasePathway InteractionsPre-ClinicalProduct DevelopmentResearch And DevelopmentAntitoxinAnthrax AntitoxinAntitoxins
Grant awards (4)
Development of a Therapeutic to Treat Anthrax in Humans$2,139,810
N01 · FY2023 · AI · contact PI
Development of a Therapeutic to Treat Anthrax in Humans$69,252
N01 · FY2021 · AI · contact PI
Development of a Therapeutic to Treat Anthrax in Humans$9,017,116
N01 · FY2020 · AI · contact PI
Development of a Therapeutic to Treat Anthrax in Humans$2,888,300
N01 · FY2019 · AI · contact PI